Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors

NCT03865082 is registered in ClinicalTrials.gov with Idera Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03865082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03865082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors
Lead sponsor
Idera Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 29, 2019
Completion date
April 30, 2022
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor